| Latest Generex Biotechnology News Headlines |
| Date | Time | Source | |
| 02/07/2007 | 7:45AM | PRNUS | Frost & Sullivan Acknowledges Generex's Path-breaking Innovations in Oral Insulin Spray Technology
PALO ALTO, Calif., Feb. 7 /PRNewswire/ -- Frost & Sullivan selected Generex Biotechnology Corporation (NASDAQ:GNBT) as the recipient of the 2006 Frost & Sullivan Award for Technology Innovation in the field of diabetic therapies. The company's Generex Oral-lyn(TM), a breakthrough oral insulin spray technology for the... More...>> |
| 12/07/2006 | 9:35AM | PRNUS | Generex Biotechnology Selects Inyx to Produce Glucose RapidSpray(TM) for Worldwide Markets
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in treating metabolic diseases via drug delivery through the inner lining of the mouth, and Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug-delivery technologies... More...>> |
| 03/09/2006 | 8:00AM | PRNUS | The Bull Market Report Investigates Companies Involved in Bird Flu Research
PRINCETON, N.J., March 9 /PRNewswire/ -- The Bull Market Report (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced that it has published an in-depth report on companies involved in bird flu research, highlighting Hemispherx Biopharma (AMEX:HEB... More...>> |
| 10/28/2005 | 11:46AM | PRNUS | Generex Biotechnology Receives $6.4 Million From Warrant Exercises
Company now has additional funding available for the launch of commercial sales of Oral-lyn(TM) in Ecuador, Phase III / IV clinical trials of Oral-lyn(TM) in Canada and Europe, and the Antigen Express avian flu vaccine project
TORONTO, Oct. 28 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT... More...>> |
| 10/04/2005 | 9:00AM | PRNUS | Generex Biotechnology Presents Clinical Trial Results at Scientific Symposia
TORONTO, Oct. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators in the Company's on-going clinical... More...>> |
| 09/29/2005 | 9:00AM | PRNUS | Generex Biotechnology Initiates Scale-up Commercial Production Run of Oral-lyn(TM)
TORONTO, Sept. 29 /PRNewswire/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, announced today that it has initiated a scale-up commercial production run of Oral-lyn(TM), the Company's proprietary oral insulin buccal spray product. Earlier this week Generex commenced... More...>> |
| 09/28/2005 | 9:21AM | PRNUS | Generex Biotechnology Issues Webcast Follow-Up
TORONTO, Sept. 28 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT) announced today that, as a follow-up to the Company's presentations of clinical data at recent European-based scientific conferences, it hosted a press conference yesterday afternoon at its Toronto offices for approximately 20... More...>> |
| 09/27/2005 | 11:33AM | PRNUS | Generex Biotechnology Corp. to Host Call Today to Update Investors on Commercialization of Oral-lyn(TM)
Conference Call and Webcast to Take Place at 2 pm Eastern Time today
TORONTO, Sept. 27 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, announced today that it will hold a conference call and webcast at 2 pm eastern time today to update interested... More...>> |
| 09/27/2005 | 8:30AM | PRNUS | Generex Biotechnology Appoints VP of Regulatory Affairs for Latin & South America
Company Augments Managerial Expertise in Connection with the Commercialization of Oral-lyn(TM)
TORONTO, Sept. 27 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Camilo Felix Gallegos has accepted an appointment as the Company's... More...>> |
| 09/20/2005 | 9:37AM | PRNUS | Generex Biotechnology Clinician To Present Clinical Trial Results at The ESPE/LWPES 7th Joint Meeting Paediatric Endocrinology
TORONTO, Sept. 20 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators in the Company's on-going clinical... More...>> |
| 09/15/2005 | 1:00PM | PRNUS | Generex Biotechnology Presents Additional Immunotherapeutics Study Results at the 41st Annual Meeting of the European Associatio
TORONTO, Sept. 15 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced further clinical trial results generated by Antigen Express, Inc., the Company's wholly-owned immunotherapeutics subsidiary.
Marta Vadacca of Universita Campus Bio-Medico... More...>> |
| 09/15/2005 | 9:11AM | PRNUS | Generex Biotechnology Presents Immunotherapeutics Study Results at the 41st Annual Meeting of the European Association for the S
TORONTO, Sept. 15 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced clinical trial results generated by Antigen Express, Inc., the Company's wholly-owned immunotherapeutics subsidiary.
Marta Vadacca of Universita Campus Bio-Medico... More...>> |
| 09/14/2005 | 2:09PM | PRNUS | Generex Biotechnology Presents Additional Oral-lyn(TM) Clinical Data at the 41st Annual Meeting of the European Association for
Oral-lyn(TM) found effective in controlling post-prandial glucose excursions
TORONTO, Sept. 14 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced additional Oral-lyn(TM) clinical trial results presented at the 41st Annual Meeting of... More...>> |
| 09/14/2005 | 9:01AM | PRNUS | Generex Biotechnology Presents Oral Insulin Clinical Data At The 41st Annual Meeting of the European Association for the Study o
Data shows that Oral-lyn(TM) and Humulin(R)R induced similar glucodynamic responses
TORONTO, Sept. 14 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced clinical trial results presented at the 41st Annual Meeting of the European Association... More...>> |
| 09/09/2005 | 9:00AM | PRNUS | Generex Biotechnology Receives Grant of Canadian Patent
Company Expands Drug Delivery Platform Patent Portfolio
TORONTO, Sept. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that it has been granted a patent by the Canadian Intellectual Property Office titled "Mixed Micellar Delivery... More...>> |
| 09/08/2005 | 10:33PM | PRNUS | Generex Biotechnology Immunotherapeutics Subsidiary to Present at the 41st Annual Meeting of The European Association for the St
TORONTO, Sept. 8 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, will make the following presentations at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD) to be held... More...>> |
| 09/07/2005 | 8:00AM | PRNUS | Generex Biotechnology Clinician to Present Clinical Trial Results at the 41st Annual Meeting of the European Association for the
TORONTO, Sept. 7 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators in the Company's on-going clinical... More...>> |
| 08/23/2005 | 8:30AM | PRNUS | Mice with Human Antigen Presenting Molecules Demonstrate Strong Responses to Novel Melanoma Peptide Vaccine Which is Destined fo
Paper on Novel Cancer Vaccine from Generex Biotechnology is Published in Prestigous Journal of Immunotherapy
TORONTO, Aug. 23 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT) announced today the publication of a milestone paper in the prestigious cancer research journal Journal of Immunotherapy... More...>> |
| 08/16/2005 | 9:01AM | PRNUS | Pandemic Influenza Vaccine Development Accelerated at Generex Biotechnology with Hire of Accomplished Senior Scientist
Novel Vaccine Technology Boosts T Helper Cell Responses to Asian Bird Flu Influenza, to Aid Some Existing Vaccines and for Use as a Stand-Alone Vaccine in Developing Countries
TORONTO, Aug. 16 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT) announced today that Antigen Express, Inc., its wholly... More...>> |
| 08/04/2005 | 9:00AM | PRNUS | Generex Biotechnology Completes Acquisition of Custom-Made, Fully-Automated Equipment for Commercial Oral-lyn(TM) Production
TORONTO, Aug. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that it has completed the acquisition of the custom-made, fully-automated equipment necessary to facilitate its initial commercial production of Oral-lyn(TM), the Company's... More...>> |